
If We Treated Tooth Decay Like We Treat Heart Disease, We’d Save Billions
Oral diseases cost Americans almost $140 billion annually. What will it take to bring these costs down?
Oral diseases cost Americans almost $140 billion annually. What will it take to bring these costs down?
The "One Big Beautiful Bill" would codify Individual Coverage Health Reimbursement Arrangements (ICHRAs) — the personalized insurance model that has transformed how employers offer health benefits — into law as CHOICE Arrangements, or Custom Health Option and Individual Care Expense arrangements.
Break down the silos. Take control of your provider data.
Allowing hospitals to repair the equipment they depend upon daily is not a step backward, but a reaffirmation of trust in the skilled and deeply committed professionals who already maintain the integrity of our healthcare systems.
ICHRA is surging in popularity as an option for employer-sponsored insurance to access the individual market, as employers rethink traditional group plans with unpredictable renewal rates and employees seek personalized healthcare. Here's a closer look at why investors and politicians are eyeing ICHRA.
How can physicians and patients be confident enough that vendors entirely ignorant of the FDA process for repair and reporting can properly recalibrate life-saving machines? Is this really the right place to argue that “anyone can do it?”
The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.
The bi-partisan passage during an election year of the End Parkinson’s Act shows that addressing a healthcare crisis, especially in our senior population, may be one of the few remaining issues that transcend party lines.
The current piecemeal state-by-state regulation approach is a feeble patchwork and ready for collapse under the first strong blow. It's high time we craft a robust and uniform effort to safeguard our patients' digital rights.
Healthcare devices must be exempted from general right to repair legislation.
Legislation introduced by Utah Senator Mike Lee would eliminate testing to show a biosimilar can be substituted for a reference biologic product. Lee contends the current testing requirement adds costs and delays market access for these lower-cost biological medicines.
AHA’s report comes after the U.S. House of Representatives passed the Improving Seniors’ Timely Access to Care Act, which would establish several requirements for the prior authorization process under MA plans. But AHA believes additional action is needed by the government.
To achieve diversity goals in research requires a multifaceted approach that makes clinical trial participation easier and uses analytics to help identify the right patients to recruit for a clinical trial.
The onus is on providers, payers and their technology partners to use the new laws and market dynamics as a catalyst to fully achieve digital transformation in healthcare and improve the patient experience.
This legislation has the potential to drastically reshape the economics of healthcare in America, but it remains unfamiliar to those it affects most—namely, patients, doctors and outpatient surgery centers.
Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.